TA871 · HST
Only if adults have 4 or more migraine days a month, at least 3 preventive drug treatments have failed, and the company provides it according to the commercial arrangement. Stop after 12 weeks if episodic migraine frequency does not reduce by at least 50%, or chronic migraine frequency does not reduce by at least 30%.
Source documents
Intervention
Conditions
Comparators
| Name | Type | Established | Committee preferred |
|---|---|---|---|
| erenumab | active drug | Yes | — |
| fremanezumab | active drug | Yes | — |
| galcanezumab | active drug | Yes | — |
Clinical trials
| Trial | Design | Phase | Pivotal |
|---|---|---|---|
| Network meta-analysis of RCTs comparing eptinezumab with erenumab, fremanezumab and galcanezumab | network meta-analysis | — | — |
Methodological decisions (1)
Cost comparison recommended based on assumption of similar clinical effectiveness between eptinezumab and other CGRP inhibitors (erenumab, fremanezumab, galcanezumab)
Committee: The committee agreed that there was sufficient evidence of similar clinical efficacy for eptinezumab compared with erenumab, fremanezumab and galcanezumab based on network meta-analysis and clinical opinion
ICER impact: negligible
Evidence gaps
Commercial arrangement
Special considerations
Cross-references